ACADIA Pharmaceuticals Inc (STU:DR6)
€ 16.37 1.79 (12.28%) Market Cap: 2.72 Bil Enterprise Value: 2.24 Bil PE Ratio: 22.05 PB Ratio: 4.96 GF Score: 73/100

ACADIA Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 03:00PM GMT
Release Date Price: €46.25 (-2.48%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning, everybody. Thanks for joining us at the, now, Virtual Bank of America Healthcare Conference. I'm Tazeen Ahmad, I'm one of the mid-biotech analysts here at the firm. It is my pleasure to introduce our next presenting company, ACADIA Pharmaceuticals. I have several members from ACADIA management here with me. Steve Davis, who is, of course, Chief Executive Officer; Michael Yang, Executive Vice President and Chief Commercial Officer; and Elena Ridloff, who is Chief Financial Officer.

Good morning, guys. Thanks so much for joining us today.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Thanks much, Tazeen, we're very pleased to participate in your conference.

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

So maybe, Steve, we have a few questions that we'd like to talk about as it relates to upcoming and recent events. But maybe you could just do a quick overview of the company's portfolio and catalyst to date,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot